The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.
Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.
advertisement
A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Custom gene therapy hints at new path for rare disease treatments
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
